Dave Johnson

Dave Johnson has more than 25 years of experience in the biopharmaceutical industry. He is currently CEO and founder of Solve Therapeutics, a monoclonal antibody-based oncology therapeutics company. Prior to Solve, Dave was chairman of the precision oncology company Lengo Therapeutics, which was acquired by Blueprint Medicines (NASDAQ: BPMC) in a deal valued at up to $465M in December 2021. Prior to Lengo, Dave was CEO of VelosBio, a precision oncology biotechnology company, which was acquired by Merck in December 2020 for $2.75B. Dave was also CEO at Acerta Pharma, a pharmaceutical company focused on covalent small-molecule technology in oncology, where he built out all facets of the corporation, to accelerate the development of Bruton tyrosine kinase inhibitor, acalabrutinib (Calquence™). Dave’s tenure at Acerta culminated in the execution of a strategic transaction with AstraZeneca valued at $7B.